Matrix’s version of this product is heat-stable and affordable, making it practical for distribution and use in warm climates.
Lopinavir/ritonavir tablets are the generic version of Abbott Laboratories’s Kaletra tablets, the brand marketed in the US and Europe, and alluvia tablets, the brand marketed in the developing world. It is used in combination with other medications to control HIV infection and is included in the antiretroviral (ARV) class of drugs known as HIV protease inhibitors.
Robert Coury, vice chairman and CEO of Mylan, said: “Mylan and Matrix are committed to our growing and high quality ARV franchise. Our goal is to provide HIV treatments to patients around the world – especially in developing countries. With Matrix’s heat-stable and affordable version of lopinavir/ritonavir, patients in remote parts of developing nations now have access to this important medicine.”